The US government collected $4.7 billion from state-legal weed businesses in 2017, according to a report from Quartz.
California is set for a major crackdown of illegal marijuana operations. Yes, they are illegal. But they’re also becoming increasingly dangerous.
In Canada, chronic pain affects 1.5 million people. As national and worldwide numbers in pain diagnoses continue to rise, innovators in the cannabis industry are developing promising therapies to address this growing market.
CFN Media sits down for an exclusive interview with InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). (VIDEO)
India Globalization Capital (NYSE AMERICAN: IGC) is developing a portfolio of products using cannabis-based “combination therapies” for the treatment of various life-altering conditions.
As one of Canada’s first licensed cannabis producers, ABcann is significantly ahead of the curve when it comes to production capacities.
As an increasing volume of scientific research leans toward the efficacy of cannabis-based drugs, innovative biotech companies are advancing their R&D to develop therapeutic candidates that envelop the potential health benefits of the marijuana plant.
InMed Pharmaceuticals, Inc. has broken new ground with an innovative, proprietary biosynthesis process that reliably creates pure cannabinoids.
InMed’s promising biosynthesis platform could put it on the radar of some major names seeking entry into one the pharmaceutical industry’s fastest-growing sectors.